Customer Service 1 (888) 261-2693
Advanced Search

Icahn's Next Biotech Blockbuster

By Dr. George Huang
Friday, December 18, 2009

Carl Icahn, the famed corporate raider, is one of my favorite investors.
 
His estimated $9 billion net worth puts him among the top-50 richest people in the world. Icahn built his fortune by taking control of struggling public companies and demanding drastic changes to revive stock prices. Icahn is notorious for firing management, initiating large special dividends, launching a new share-repurchase program, or simply breaking companies up to sell the parts to the highest bidders.
 
While his track record isn't perfect, his aggressive style often scares incompetent management and board members into adopting new shareholder-friendly tactics.
 
Over the last five years, Icahn has focused much of his efforts on biotechs – my specialty. He targets companies with breakthrough drugs... and questionable management. His most recent triumph was ImClone, maker of the blockbuster cancer drug Erbitux (and the stock that sent Martha Stewart to jail).
 
Icahn ousted ImClone's corrupt, incompetent management and made himself chairman. In 2008, he engineered a bidding war and sold the company to Eli Lilly for over $6 billion. In the process, he booked $500 million profit. My FDA Report subscribers pocketed 100% gains in one month from his triumph.
 
While he was working his magic with ImClone, Icahn also turned his attention to Amylin, a $2 billion biotech. Amylin markets the breakthrough diabetes drug Byetta, which pulls in $650 million in annual sales.
 
Derived from the saliva of the Gila monster (a venomous lizard), Byetta is the first in a new class of diabetes drugs. It can lower blood sugar without the risk of overshooting, a serious side effect of many current diabetes medications. Even better, unlike most diabetes drugs, Byetta helps patients lose weight – an average 11 pounds.
 
Despite its clinical advantages, Byetta's twice-a-day injection has limited appeal except for the sickest patients. So sales have stalled. To overcome these problems, Amylin and its partner, Eli Lilly, developed a long-acting formulation of Byetta, also known as "LAR." It's twice as potent as the original and patients only need to inject it once a week.
 
Amylin has submitted a new drug application for LAR with the FDA. The decision date is March 5. If approved, LAR will be a mega-blockbuster, with worldwide peak sales surpassing $2 billion. This huge potential is what attracted Carl Icahn to Amylin.
 
After a nasty confrontation in June, Icahn ousted Amylin's chairman and put two of his people on the board. The current management has taken notice and started trimming excess costs as the first move to boost shareholder returns. But the biggest potential rests with LAR...
 
If the FDA approves the drug in March, Amylin shares could soar 50% in a single day. And Icahn would likely engineer a sale to partner Eli Lilly. A rejection, on the other hand, could result in a 20%-40% beating.
 
I think the odds favor an approval... But at current prices, Amylin stock still has too much downside risk. I'd be willing to speculate at $10 per share or below. And as March approaches, I'll be looking for a cheap option trade.
 
Even if we never get a shot at Amylin, we've got plenty of ways to follow Icahn into profits next year...
 
He's been making noise at large biotechs like Genzyme, Biogen, and Forest Labs. You can bet those management teams will have a nerve-wracking 2010. Hopefully, that'll be to our benefit.
 
Good investing,
 
George Huang




In The Daily Crux
Market Notes
Natural gas stockpiles shrink... natty races 6% higher.
 
Gold slips 2.5%... down 9% from December 3 high of $1,218.30 per ounce.
 
Big hospital managers HealthSouth and LifePoint reach new highs... up over 10% this month.
 
Earnings today... CarMax, Carnival, Darden Restaurants.
Market Watch
Symbol Price
Change
52-Wk
S&P 500 1221.53 +1.3% +10.1%
Oil 38.31 +1.4% -0.6%
Gold 138.07 +2.1% +16.3%
Silver 28.60 +2.4% +53.6%
US-Dollar 80.67 -0.8% +8.1%
Euro 1.32 +0.6% -12.1%
Volatility 18.01 -7.1% -19.8%
Gold Stocks 581.56 +3.0% +17.0%
10-Year Yield 3.02 +0.7% -10.7%

World ETFs
Symbol Price
Change
52-Wk
USA 122.89 +0.3% +11.3%
Canada 30.50 +0.2% +16.2%
Russia 21.94 +1.4% +18.1%
India 37.85 +0.3% +22.3%
Israel 16.69 +1.3% +10.8%
Japan 10.64 +0.6% +6.5%
Singapore 13.73 -1.1% +18.8%
Taiwan 14.78 +0.4% +19.2%
S. Korea 57.31 +1.3% +23.4%
S. Africa 71.87 +1.4% +28.2%
China 44.42 -1.4% -0.6%
Lat.America 53.17 +0.7% +8.4%

Sector ETFs
Symbol Price
Change
52-Wk
Oil Service 137.59 +1.0% +18.9%
Big Pharma 64.14 +0.0% -3.2%
Internet 72.07 -0.1% +23.4%
Semis 16.22 +1.2% +29.4%
Utilities 31.28 +0.2% +1.5%
Defense 18.52 +0.1% +10.6%
Nanotech 10.03 +0.4% +1.6%
Alt. Energy 10.08 +1.3% -3.3%
Water 18.49 +1.0% +14.5%
Insurance 16.14 +0.4% +21.1%
Biotech 20.54 -0.2% +28.1%
Retail 19.70 +0.3% +30.2%
Software 24.79 +0.8% +25.9%
Big Tech 53.87 +0.3% +22.7%
Construction 13.10 +0.9% +15.7%
Media 13.64 +0.5% +26.0%
Consumer Svcs 67.39 +0.2% +24.5%
Financials 55.04 +0.3% +7.4%
Health Care 64.30 +0.1% +2.0%
Industrials 63.54 +0.5% +21.0%
Basic Mat 74.35 +1.1% +25.3%
Real Estate 55.32 +0.1% +25.0%
Transportation 91.77 +0.7% +26.9%
Telecom 22.59 +0.5% +17.8%

Recent Articles